Literature DB >> 23604228

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

M Nieborowska-Skorska1, G Hoser, A Hochhaus, T Stoklosa, T Skorski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23604228      PMCID： PMC4041198          DOI： 10.1038/leu.2013.123

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Authors:  Elisabeth Bolton-Gillespie; Mirle Schemionek; Hans-Ulrich Klein; Sylwia Flis; Grazyna Hoser; Thoralf Lange; Margaret Nieborowska-Skorska; Jacqueline Maier; Linda Kerstiens; Mateusz Koptyra; Martin C Müller; Hardik Modi; Tomasz Stoklosa; Ilona Seferynska; Ravi Bhatia; Tessa L Holyoake; Steffen Koschmieder; Tomasz Skorski
Journal:  Blood       Date:  2013-03-29       Impact factor: 22.113

2.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Authors:  Margaret Nieborowska-Skorska; Piotr K Kopinski; Regina Ray; Grazyna Hoser; Danielle Ngaba; Sylwia Flis; Kimberly Cramer; Mamatha M Reddy; Mateusz Koptyra; Tyrone Penserga; Eliza Glodkowska-Mrowka; Elisabeth Bolton; Tessa L Holyoake; Connie J Eaves; Sabine Cerny-Reiterer; Peter Valent; Andreas Hochhaus; Timothy P Hughes; Heiko van der Kuip; Martin Sattler; Wieslaw Wiktor-Jedrzejczak; Christine Richardson; Adrienne Dorrance; Tomasz Stoklosa; David A Williams; Tomasz Skorski
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

3.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 4.  Free radicals and antioxidants in the year 2000. A historical look to the future.

Authors:  J M Gutteridge; B Halliwell
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Authors:  Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

6.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

Review 7.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

Review 8.  Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.

Authors:  A Hochhaus; P La Rosée
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

Review 9.  Advances in the treatment of chronic myeloid leukemia.

Authors:  Anna M Eiring; Jamshid S Khorashad; Kimberly Morley; Michael W Deininger
Journal:  BMC Med       Date:  2011-08-26       Impact factor: 8.775

10.  The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Authors:  Christopher A Eide; Lauren T Adrian; Jeffrey W Tyner; Mary Mac Partlin; David J Anderson; Scott C Wise; Bryan D Smith; Peter A Petillo; Daniel L Flynn; Michael W N Deininger; Thomas O'Hare; Brian J Druker
Journal:  Cancer Res       Date:  2011-04-19       Impact factor: 12.701
View more
  4 in total

1.  Selenium suppresses leukemia through the action of endogenous eicosanoids.

Authors:  Ujjawal H Gandhi; Naveen Kaushal; Shailaja Hegde; Emily R Finch; Avinash K Kudva; Mary J Kennett; Craig T Jordan; Robert F Paulson; K Sandeep Prabhu
Journal:  Cancer Res       Date:  2014-05-28       Impact factor: 12.701

2.  AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.

Authors:  M Nieborowska-Skorska; S Flis; T Skorski
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528

Review 3.  Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy.

Authors:  Emanuela Andretta; Caterina Costa; Consiglia Longobardi; Sara Damiano; Antonio Giordano; Francesco Pagnini; Serena Montagnaro; Massimiliano Quintiliani; Chiara Lauritano; Roberto Ciarcia
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

Review 4.  DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.

Authors:  Elzbieta Pawlowska; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.